Skip to main content
. 2017 Jun 2;17:206. doi: 10.1186/s12888-017-1362-7

Fig. 1.

Fig. 1

Trial flow. Randomized, placebo-controlled, double-blind clinical trial with 5 phases of examination: T0) Screening; T1) Baseline, 12 weekly SST in combination with OXT vs. 12 weekly SST without OXT; T2) Post-assessment; T3) Follow-up 3 months after end of treatment; T4) follow-up 6 months after end of treatment